First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB

First Trust Advisors LP trimmed its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 4.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,687,388 shares of the company’s stock after selling 82,922 shares during the period. First Trust Advisors LP owned approximately 0.26% of Genmab A/S worth $51,752,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vise Technologies Inc. purchased a new position in shares of Genmab A/S in the 2nd quarter worth approximately $299,000. ABC Arbitrage SA purchased a new position in Genmab A/S during the second quarter worth $9,236,000. Creative Planning boosted its stake in Genmab A/S by 11.8% during the second quarter. Creative Planning now owns 65,132 shares of the company’s stock worth $1,346,000 after buying an additional 6,870 shares during the period. Rockefeller Capital Management L.P. bought a new position in Genmab A/S during the second quarter valued at $267,000. Finally, JPMorgan Chase & Co. increased its position in Genmab A/S by 17.0% during the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock valued at $19,282,000 after acquiring an additional 135,814 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Down 2.1%

Shares of NASDAQ GMAB opened at $27.38 on Thursday. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $35.43. The firm has a market cap of $17.59 billion, a PE ratio of 17.66, a price-to-earnings-growth ratio of 1.15 and a beta of 0.94. The business has a fifty day simple moving average of $31.13 and a two-hundred day simple moving average of $30.47. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. Analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company started coverage on shares of Genmab A/S in a report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 target price for the company. HC Wainwright upped their price target on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Morgan Stanley started coverage on shares of Genmab A/S in a research report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price objective on the stock. Jefferies Financial Group began coverage on Genmab A/S in a research report on Tuesday, February 17th. They set a “buy” rating and a $41.50 target price for the company. Finally, Guggenheim cut their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.58.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.